{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T10:34:09Z","timestamp":1721039649790},"reference-count":0,"publisher":"National Library of Serbia","issue":"suppl. 1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Srp Arh Celok Lek","SRP ARH CELOK LEK","SRP ARK CELOK LEK","SRPSKI ARHIV CELOKUP"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>The clinical efficacy of antiplatelet therapy (aspirin, P2Y12 and\n   glycoprotein IIb\/IIIa receptor antagonists) to prevent occlusive arterial\n   events in patients with atherothrombotic disease is well established. Despite\n   the proven benefits of antiplatelet therapy, many patients continue to\n   experience arterial events. Many factors may influence the response of\n   platelets to antiplatelet therapy and some patients with adequate compliance\n   to the treatment may exhibit failure of platelet inhibition as determined by\n   ex vivo laboratory tests, a phenomenon termed ?resistance?to antiplatelet\n   therapy. Platelet function can be measured by numerous platelet function\n   tests, with which various parameters of platelet activation, secretion,\n   adhesion and aggregation can be determined. These tests include light\n   transmission (optical) and whole blood aggregometry, point-of-care devices,\n   such as platelet function analyzers PFA-100?, and VerifyNow?, flow cytometry,\n   serum thromboxane B2 and urinary levels of the thromboxane B2 metabolite\n   11-dehyro-thromboxane B2. Other tests, such as whole blood platelet\n   aggregation measured by platelet counting, thrombelastography and devices\n   such as the cone and plate(let) analyzer, Plateletworks and thrombotic status\n   analyzer have also been used to determine platelet inhibition by antiplatelet\n   drugs, but their use is not widespread and therefore experience is limited.\n   Further studies need to be carried out to answer basic questions on the\n   clinical utility and cost-effectiveness of laboratory monitoring of\n   antiplatelet therapy before it can be recommended in clinical practice.<\/jats:p>","DOI":"10.2298\/sarh10s1059s","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T12:52:43Z","timestamp":1437569563000},"page":"59-63","source":"Crossref","is-referenced-by-count":5,"title":["Platelet function tests and resistance to antiplatelet therapy"],"prefix":"10.2298","volume":"138","author":[{"given":"Mojca","family":"Stegnar","sequence":"first","affiliation":[{"name":"University Medical Centre, Department of Vascular Diseases, Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1078","container-title":["Srpski arhiv za celokupno lekarstvo"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T10:28:51Z","timestamp":1685356131000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0370-817910059S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":0,"journal-issue":{"issue":"suppl. 1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2298\/sarh10s1059s","relation":{},"ISSN":["0370-8179","2406-0895"],"issn-type":[{"value":"0370-8179","type":"print"},{"value":"2406-0895","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}